NEW YORK, Sept. 3-SurroMed has launched a research collaboration with Eli Lilly to identify new biomarkers, the company said today.
Lilly will supply biological samples, which SurroMed will analyze using its mass spectrometry-based platform.
The collaboration is broad, seeking to identify biomarkers that are relevant to drug development and disease progression.
Financial details of the agreement were not revealed.
SurroMed is based in Mountain View, Calif.